Secuenciación de nueva generación para identificar mutaciones accionables en el cáncer de pulmón de células no pequeñas: un protocolo para revisión sistemática y metanálisisélulas No Pequeñas: Una Revisión Sistemática y Meta-Análisis

Introduction: Non-small cell lung cancer (NSCLC) is the most prevalent phenotype of pulmonary neoplasm. This study aims to review the efficacy of Next-generation sequencing (NGS) compared to other techniques for identifying actionable mutations in tissue tumor samples or circulating tumor DNA (ctDNA) blood samples from NSCLC patients eligible for systemic therapy. Methods and Analysis: We will identify eligible diagnostic test studies using a predefined search strategy in Medline and PubMed. We will extract individual study results to calculate the diagnostic performance values of the test, such as sensitivity, specificity, and predictive value. NGS’s diagnostic performance will be compared with techniques recommended by NCCN and ESMO guidelines. The review and meta-analysis will adhere to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA-P) guidelines. Discussion: Identifying actionable mutations in tumor samples is crucial for managing advanced NSCLC. NGS offers benefits by detecting multiple genetic alterations simultaneously, though its high cost and time requirements hinder widespread use. Our systematic review will evaluate NGS’s diagnostic accuracy and clinical benefits compared to other techniques, considering factors like test turnaround time. To address challenges such as the difficulty in obtaining detailed patient data and interpreting mutations of uncertain clinical significance, we will seek evidence from clinical studies and guidelines to provide comprehensive insights.